الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
LACC represents a main problem in developing countries where lacking of access to screening programs and health facilities resulted in diagnosis of most cases in advanced stages.
CCR is considered the standard treatment of LACC but despite achieving a good PFS, OS and response rate, the incidence of hematological and gastrointestinal toxicities is still high.
NAC followed by CCR and HDR BT was compared to the standard CCR followed by HDR BT in our study, and it achieved a high partial response rate and overall response rate; however, the PFS was non significantly lower compared to the standard arm. All the patients in the study survived with the 2 years OS of 100%.
The results of our study compared to the available similar studies showed a higher ORR and PFS with the advantage of the NAC in our patients to start with in case of non availability of radiotherapy machine and enhancing tumor coverage and sparing organ at risks in the EBRT planning of whole pelvis radiotherapy due to the response achieved.
A dosimetric comparison between the HDR BT boost and the VMAT boost was done and showed that the VMAT boost achieved more homogenous tumor coverage with more sparing to the OARs. It was suggested that the VMAT boost can be used in case of absence BT or refusal of BT by the patients. It needs to be studied on a larger number of patients and compare the clinical application of the VMAT, not only dosimetric comparison.